Ligand efficiency as a guide in fragment hit selection and optimization

Drug Discovery Today: Technologies

Volumn 7, Issue 3, 2010, Pages

  Schultes, Sabine ^a   De Graaf, Chris ^b   Haaksma, Eric E J ^a,b   De Esch, Iwan J P ^b   Leurs, Rob ^b   Krämer, Oliver ^a  

^a BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND;

ARTICLE; BINDING AFFINITY; HIGH THROUGHPUT SCREENING; LIGAND BINDING; LIPOPHILICITY; MOLECULAR WEIGHT; PROCESS OPTIMIZATION;

EID: 78650742572     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2010.11.003     Document Type: Review

References (41)

1. R.A. Goodnow Jr. Hit and lead identification: integrated technology-based approaches Drug Discov. Today: Technol. 3 2006 367 375
2. R.S. Bohacek The art and practice of structure-based drug design: a molecular modeling perspective Med. Res. Rev. 16 1996 3 50
3. C.M. Dobson Chemical space and biology Nature 432 2004 824 828
4. R.A. Carr Fragment-based lead discovery: leads by design Drug Discov. Today 10 2005 987 992
5. M. Congreve Recent developments in fragment-based drug discovery J. Med. Chem. 51 2008 3661 3680
6. G.E. de Kloe Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discov. Today 14 2009 630 646
7. D.A. Erlanson Fragment-based drug discovery J. Med. Chem. 47 2004 3463 3482
8. D.A. Erlanson Fragment-based lead discovery: a chemical update Curr. Opin. Biotechnol. 17 2006 643 652
9. P.J. Hajduk SAR by NMR: putting the pieces together Mol. Interv. 6 2006 266 272
10. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
11. H. Jhoti Fragment-based screening using X-ray crystallography and NMR spectroscopy Curr. Opin. Chem. Biol. 11 2007 485 493
12. A.R. Leach Fragment screening: an introduction Mol. Biosyst. 2 2006 430 446
13. M. Orita Advances in fragment-based drug discovery platforms Expert Opin. Drug Discov. 4 2010 1125 1144
14. D.C. Rees Fragment-based lead discovery Nat. Rev. Drug Discov. 3 2004 660 672
15. E.R. Zartler, and M.J. Shapiro Fragonomics: fragment-based drug discovery Curr. Opin. Chem. Biol. 9 2005 366 370
16. T. Fink Virtual exploration of the small-molecule chemical universe below 160 Daltons Angew. Chem. Int. Ed. Engl. 44 2005 1504 1508
17. T. Fink, and J.L. Reymond Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26. 4 million structures (110. 9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery J. Chem. Inf. Model. 47 2007 342 353
18. M.M. Hann Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 41 2001 856 864
19. G.M. Keseru, and G.M. Makara The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discov. 8 2009 203 212
20. A.J. Ruben Overcoming roadblocks in lead optimization: a thermodynamic perspective Chem. Biol. Drug Des. 67 2006 2 4
21. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Del. Rev. 23 1997 3 25
22. M.C. Wenlock A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250 1256
23. M.P. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 51 2008 817 834
24. A.L. Hopkins Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
25. C. Abad-Zapatero, and J.T. Metz Ligand efficiency indices as guideposts for drug discovery Drug Discov. Today 10 2005 464 469
26. M.L. Verdonk, and D.C. Rees Group efficiency: a guideline for hits-to-leads chemistry ChemMedChem 3 2008 1179 1180
27. C.H. Reynolds The role of molecular size in ligand efficiency Bioorg. Med. Chem. Lett. 17 2007 4258 4261
28. J.J. Goodnow The role of past events in problem solving J. Exp. Psychol. 58 1959 456 461
29. C.H. Reynolds Ligand binding efficiency: trends, physical basis, and implications J. Med. Chem. 51 2008 2432 2438
30. J.W. Nissink Simple size-independent measure of ligand efficiency J. Chem. Inf. Model. 49 2009 1617 1622
31. M. Orita 'Golden Ratio' indices in fragment-based drug discovery Drug Discov. Today 14 2009 321 328
32. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890
33. Kenny P. Scaling potency by lipophilicity and molecular size. http://fbdd-lit.blogspot.com/2009/06/scaling-potency-by-lipophilicity-and.html. 2009. Ref Type: Internet Communication
34. M. Congreve A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 8 2003 876 877
35. P.J. Hajduk Fragment-based drug design: how big is too big? J. Med. Chem. 49 2006 6972 6976
36. S.D. Bembenek Ligand efficiency and fragment-based drug discovery Drug Discov. Today 14 2009 278 283
37. J.D. Hughes Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18 2008 4872 4875
38. S. Howard Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity J. Med. Chem. 52 2009 379 388
39. G.L. Card A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design Nat. Biotechnol. 23 2005 201 207
40. A. Gill The discovery of novel protein kinase inhibitors by using fragment-based high-throughput X-ray crystallography Chembiochem 6 2005 506 512
41. A.L. Gill Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation J. Med. Chem. 48 2005 414 426